For 18 years, Truffle Capital has been creating and financing to success radical and disruptive innovations in two fields of expertise, Life Sciences and Information Technologies. These creations revolutionize their sectors and will become the tomorrow’s leaders.
Truffle Capital is the only European Fund to support its innovations from creation to commercial success.
Truffle Capital works closely with the world's best 50 universities to select and transform their most significant inventions into major technological innovations, novel medical devices and effective drug treatments.
In terms of Information technologies, Truffle Capital has focused in FinTechs since 2014. Thanks to its team of dedicated experts, Truffle is able to select products & services with underlying complex technologies (deep tech).
Carmat sells its artificial heart for the first time in Italy
The autonomous bioprosthesis created by the French firm has been implanted on a patient in Naples.
Philippe Pouletty appears in Stanford OTL - 50th Anniversary Annual Report
Philippe Pouletty and his work on polymerase chain reaction (PCR) is featured in the Stanford OTL 50th Anniversary Annual Report
PROMISING PHARMA PLAYS FOR INVESTORS
The success of the messenger RNA vaccines for Covid-19 developed by Pfizer Inc. (PFE) and Moderna...
Holistick raises $5M to boost preclinical development of PFO closure device
Truffle Capital reports outstanding 2020 stock market performance for its listed BioMedTech portfolio companies
Three companies founded or co-founded by Truffle represent 30% of the total valuation of the highest BioMedTech market caps of Euronext Paris...
Discussion of Abivax Clinical Program involving Covid-19, Ulcerative Colitis, Crohn’s Disease and more
Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn’s Disease...